Read by QxMD icon Read


Oronzo Brunetti, Claudio Luchini, Antonella Argentiero, Stefania Tommasi, Anita Mangia, Giuseppe Aprile, Paolo Marchetti, Enrico Vasile, Andrea Casadei Gardini, Mario Scartozzi, Sandro Barni, Sara Delfanti, Fernando De Vita, Francesco Di Costanzo, Michele Milella, Chiara Alessandra Cella, Rossana Berardi, Ivana Cataldo, Daniele Santini, Claudio Doglioni, Evaristo Maiello, Rita T Lawlor, Vincenzo Mazzaferro, Sara Lonardi, Felice Giuliante, Giovanni Brandi, Aldo Scarpa, Stefano Cascinu, Nicola Silvestris
INTRODUCTION: Exocrine pancreatic cancers include common type pancreatic ductal adenocarcinoma and cystic neoplasms, which account for 85% and 10% of cases, respectively. The remaining 5% are rare histotypes, comprising adenosquamous carcinoma, acinar cell carcinoma, signet ring cell carcinoma, medullary carcinoma, pancreatoblastoma, hepatoid carcinoma, undifferentiated carcinoma and its variant with osteoclast-like giant cells, solid pseudopapillary carcinoma, and carcinosarcoma. Due to their low incidence, little knowledge is available on their clinical and molecular features as well as on treatment choices...
April 9, 2019: Tumori
Luigi Celio, Gabriella Saibene, Stefano Lepori, Fabrizio Festinese, Monica Niger, Francesco Raspagliesi, Domenica Lorusso
PURPOSE: To explore efficacy of short-course olanzapine with or without low-dose dexamethasone for prevention of delayed emesis in gynecologic cancer patients receiving carboplatin/paclitaxel. METHODS: This was a prospective study in 81 chemo-naive patients receiving 0.25 mg intravenous palonosetron, 16 mg dexamethasone, and 10 mg oral olanzapine before chemotherapy. On days 2 and 3, patients randomly received 10 mg olanzapine (arm A; n=27), 10 mg olanzapine plus 4 mg dexamethasone (arm B; n=27), or 8 mg dexamethasone (reference arm C; n=27)...
April 4, 2019: Tumori
Yanan Jiang, Zhaoyi Miao, Jinhuan Wang, Jing Chen, Yangyang Lv, Donghui Xing, Xiaofang Wang, Yafei Wang, Zeng Cao, Zhigang Zhao
OBJECTIVE: Patients with non-Hodgkin lymphoma (NHL) occasionally present with multiple primary malignant tumors (MPMTs). This study aimed to determine the clinical characteristics, survival, and risk factors of these patients. METHODS: The median follow-up of 92 patients was 13.5 months (range 0.3-72). Overall, 21 patients had synchronous MPMTs and 71 had metachronous MPMTs. We classified patients in the latter group into metachronous first group (n=27) and metachronous second group (n=44)...
April 4, 2019: Tumori
Kun Chen, Juan Wang, Jinzhen Dai, Ailin Luo, Yuke Tian, Zhonghui Guan, Xueren Wang
OBJECTIVE: To investigate the perioperative anesthetic management of patients diagnosed with renal cell carcinoma (RCC) metastasized into the renal vein or inferior vena cava (IVC) after undergoing radical nephrectomy to provide clinical evidence for rational anesthetic interventions. METHODS: A total of 81 patients with RCC extending into the renal vein or IVC, aged 17-73 years, undergoing radical nephrectomy were recruited. Preoperative status, intraoperative management, average operation time, average estimated blood loss, postanesthesia outcomes, and postoperative complications were retrospectively analyzed...
April 2, 2019: Tumori
Snjezana Janjetovic, Anne Marie Asemissen, Frank Dicker, Mascha Binder, Judith Dierlamm, Carsten Bokemeyer, Philippe Schafhausen
BACKGROUND: Progression of chronic myeloid leukemia (CML) is frequently accompanied by cytogenetic evolution, with an extra copy of the Philadelphia chromosome, trisomy 8 and 19, and isochromosome (17p) commonly detected. Translocations involving 11q23 chromosomal region have been rarely reported in CML. The few reported patients with blast crisis (BC) of CML carrying an 11q rearrangement have insufficient responses to tyrosine kinase inhibitors (TKIs) and possess a poor prognosis. CASE REPORT: We report the case of a 30-year-old man with CML who had a fulminant myeloid BC 4 months after initiation of first-line therapy with the TKI dasatinib, despite showing an optimal response at the 3-month timepoint...
April 1, 2019: Tumori
Fabio Marazzi, Valeria Masiello, Domenico Marchesano, Luca Boldrini, Stefano Luzi, Paola E Ferrara, Eugenia Amabile, Danila Piccari, Francesco Landi, Francesca Moschella, Gianluca Franceschini, Riccardo Masetti, Giovanna Mantini, Vincenzo Valentini, Daniela Smaniotto
BACKGROUND: Pain and functional impairment of the ipsilateral shoulder girdle in patients who underwent surgery and radiotherapy for breast cancer (BC) is a late complication reported in the literature. We analyze a correlation with dosimetric parameters and propose an algorithm for sparing strategies. METHODS: A total of 111 patients treated for BC were included in this observational analysis during follow-up protocol visits. Exclusion criteria were the presence of moderate or severe arthrosis history and/or rheumatologic diseases...
April 1, 2019: Tumori
Rosa Falcone, Adriana Romiti, Marco Filetti, Michela Roberto, Riccardo Righini, Andrea Botticelli, Emanuela Pilozzi, Michele Ghidini, Claudio Pizzo, Federica Mazzuca, Paolo Marchetti
BACKGROUND: Because of a lack of large-scale prospective studies there is no clear indication about the management of patients with small bowel adenocarcinoma (SBA). This study evaluated clinical outcome of patients diagnosed with SBA at our institution. METHODS: Clinicopathologic features, treatments, and clinical outcome of patients diagnosed with SBA between 2006 and 2017 were retrospectively analyzed. Median time of survival was calculated and compared using the log-rank test...
April 1, 2019: Tumori
Emre Akar, Mehmet Haluk Yücel, Tunahan Şahin, Deniz Tural
BACKGROUND: Cytotoxic and immunosuppressive therapies for cancer treatment may allow hepatitis reactivation. Hepatitis due to viral hepatitis reactivation is detected in 14%-25% of hepatitis B surface antigen (HBsAg)-positive cancer patients undergoing anticancer treatments. Drug toxicity may be confused with hepatitis reactivation, which may cause a delay in diagnosis. CASE REPORT: A 60-year-old man with metastatic renal cell carcinoma was treated with sunitinib...
April 1, 2019: Tumori
Di Wang, Yang Luo, Di Shen, Lin Yang, Hui-Ying Liu, Yi-Qun Che
BACKGROUND: Bone marrow metastasis occurs in lung adenocarcinoma patients with a poor prognosis due to the late course and lack of definitive treatments, although reports on this are limited. This study analyzed the clinical manifestation, laboratory examination, treatment, and prognosis of patients with lung adenocarcinoma with bone marrow metastasis. METHODS: All patients were confirmed to have bone marrow infiltration by bone marrow aspiration. The clinical data of 12 patients with lung adenocarcinoma with bone marrow metastasis were analyzed retrospectively...
April 1, 2019: Tumori
Chiara Panato, Diego Serraino, Emilia De Santis, Ornella Forgiarini, Tiziana Angelin, Ettore Bidoli, Loris Zanier, Stefania Del Zotto, Salvatore Vaccarella, Silvia Franceschi, Luigino Dal Maso
BACKGROUND: Incidence rates of thyroid cancer (TC) increased in the last decades worldwide. This study aimed to describe TC incidence in the Friuli Venezia Giulia (FVG) region, to estimate the quota of overdiagnosis, and to investigate the impact of surgery on long-term survival after TC diagnosis. METHODS: TC cases reported to the FVG population-based cancer registry during 2002-2013, aged <85 years, were included. Age standardized rates (ASR) on the European population were computed, while proportion of TC overdiagnosis was estimated in comparison with expected age-specific incidence rates from published time series...
March 28, 2019: Tumori
Domenica Lorusso, Ilaria Sabatucci, Giuseppa Maltese, Stefano Lepori, Elisa Tripodi, Giorgio Bogani, Francesco Raspagliesi
The vast majority of ovarian cancer relapses on front-line therapy and the optimal treatment of recurrent ovarian cancer remains controversial. This review is based on the relevant published literature indexed in PubMed on pegylated liposomal doxorubicin (PLD), either alone or in combination with other drugs, as one option in relapsed disease. PLD showed an improved pharmacokinetic profile, with a slower plasma clearance and a longer circulation time, compared to other conventional doxorubicin formulations...
March 28, 2019: Tumori
Manuel Zorzi, Luigino Dal Maso, Silvia Francisci, Carlotta Buzzoni, Massimo Rugge, Stefano Guzzinati
OBJECTIVE: To evaluate the trends of colorectal cancer (CRC) incidence and mortality rates from 2003 to 2014 in Italy by age groups and regions. METHODS: We used the data of 48 cancer registries from 17 Italian regions to estimate standardized incidence and mortality rates overall and by sex, age groups (<50, 50-69, 70+ years), and geographic area (northwest, northeast, center, south, and islands). Time trends were expressed as annual percent change in rates (APC) with 95% confidence intervals (95% CI)...
March 27, 2019: Tumori
Gunsu Kimyon Comert, Osman Turkmen, Cigdem Guler Mesci, Alper Karalok, Ozge Sever, Selcan Sinaci, Nurettin Boran, Derman Basaran, Taner Turan
OBJECTIVE: To evaluate the factors predicting oncologic outcomes in low-grade ovarian serous carcinoma (LGOSC). METHODS: Seventy patients with LGOSC were included in the study. According to the residual disease present at the end of the initial cytoreductive surgery (CRS), surgical outcomes are defined as follows: maximal CRS for absence of macroscopic residual tumors, optimal CRS for macroscopic residual tumors with diameters ranging from 0.1 to ⩽1 cm diameter, and suboptimal CRS for macroscopic residual tumors measuring >1 cm in diameter...
March 27, 2019: Tumori
Eliana La Rocca, Vanessa Lici, Tommaso Giandini, Francesca Bonfantini, Sarah Frasca, Michela Dispinzieri, Massimiliano Gennaro, S Serena Di Cosimo, Laura Lozza, Emanuele Pignoli, Riccardo Valdagni, Maria Carmen De Santis
PURPOSE: To examine interobserver variability between the radiation oncologist (RTO) and the radiation therapist (RTT) in delineating the tumor bed (TB) in early breast cancer (BC). METHODS: We retrospectively analyzed patients who received a radiotherapy boost to the TB. In a first group, the clinical target volume (CTV) for the boost was the surgical bed, defined by using surgical clips. In a second group, the CTV was defined by identifying a seroma cavity or a metallic find on the scar...
March 27, 2019: Tumori
Federica Grosso, Alessandro Croce, Roberta Libener, Narciso Mariani, Massimo Pastormerlo, Antonio Maconi, Caterina Rinaudo
PURPOSE: To assess whether asbestos fibers may be observed in liver tissue of patients with cholangiocarcinoma (CC) with environmental or working asbestos exposure. METHODS: Detection of fibers was performed directly on histologic sections of liver from 7 patients with CC using optical microscope and variable pressure scanning electron microscopy equipped with energy-dispersive spectroscopy (VP-SEM/EDS). All patients were from Casale Monferrato, Italy, a highly asbestos-polluted town...
March 27, 2019: Tumori
Lorenzo Livi, Beatrice Detti, Giulio Francolini, Francesca Terziani, Luca Triggiani, Rolando M D'Angelillo, Gianluca Ingrosso
Prostate cancer is the second most frequent cancer worldwide, with a very high rate of progression despite treatment. The most aggressive form of the disease is known as castration-resistant prostate cancer, which carries a poor prognosis. We reviewed available literature regarding the combination of abiraterone acetate antihormonal drug and ablative radiation therapy for the treatment of metastatic castration-resistant prostate cancer. This dual treatment may enhance the effects of second-line hormonal therapy, as radiotherapy renders cancer cells more prone to immune-mediated cytotoxicity...
March 25, 2019: Tumori
Byoung Soo Kwon, Ji Hyun Park, Seulgi Kim, Sojung Park, Wonjun Ji, Woo Sung Kim, Jae Cheol Lee, Yu Rang Park, Chang-Min Choi
BACKGROUND: This study aimed to estimate therapeutic effects of first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in real-world practice, by analyzing survival outcomes in an unselected, Korean female population with advanced lung cancer based on the National Health Insurance Service database. METHODS: We identified women with newly diagnosed advanced lung cancer from January 2004 to December 2013. For progression-free survival (PFS) and overall survival (OS) analyses, patients were defined into the following subgroups: group A, treated with first-generation EGFR-TKI ⩾6 months; group B, treated with EGFR-TKIs <6 months but at least >1 month; and group C, treated with cytotoxic chemotherapy as follows: monotherapy or combination therapy with gemcitabine or pemetrexed; or monotherapy with docetaxel, paclitaxel, or vinorelbine...
March 25, 2019: Tumori
Laura Botta, Gemma Gatta, Annalisa Trama, Riccardo Capocaccia
BACKGROUND: The proportion of patients cured of cancer is usually estimated with cure models assuming they have the same death risk as the general population. These patients, even when cured, often maintain an extra death risk compared to the overall population. Our aims were to estimate this extra risk, and to take it into account in estimating cure proportions and relative survival (RS). METHODS: We used RS mixture model with an additional parameter expressing the extra noncancer death risk of patients, assumed constant with age...
March 25, 2019: Tumori
Juan A Muñoz-Largacha, Sowmya R Rao, Laurence H Brinckerhoff, Benedict D Daly, Hiran C Fernando, Virginia R Litle, Kei Suzuki
OBJECTIVE: To determine if induction chemotherapy with concurrent high-dose radiation followed by resection is associated with improved survival in patients with nonsuperior sulcus lung cancer with chest wall invasion. METHODS: We performed a retrospective review of clinical T3 (chest wall invasion) N0/N1 patients with non-small cell lung cancer who underwent surgical resection between January 1, 1992, and January 31, 2017. Exclusion criteria included superior sulcus tumors and resection performed for palliation/recurrence...
March 25, 2019: Tumori
Roberto Lisi, Gessica Abate, Pasqualina D'Urso, Maria Teresa Martinetti, Benedetta Siniscalchi, Francesco Marampon, Nadia Bulzonetti, Vincenzo Tombolini
BACKGROUND: Inflammatory myofibroblastic tumor (IMT) is a rare benign cancer that can express a more aggressive phenotype related to the genetic mutation of the anaplastic lymphoma kinase receptor (ALK). Involvement of trachea is extremely rare and due to the clinical and radiologic nonspecificity, the definitive diagnosis is based on the histologic evaluation of tissue specimens. Total surgical excision is curative and chemotherapy or radiotherapy has been employed in the treatment of unresectable tumors or as adjuvant therapies...
March 22, 2019: Tumori
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"